Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) Director Sells 3,000 Shares of Stock

United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) Director Raymond Dwek sold 3,000 shares of the stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $285.57, for a total transaction of $856,710.00. Following the completion of the sale, the director now directly owns 1,750 shares in the company, valued at approximately $499,747.50. The trade was a 63.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Raymond Dwek also recently made the following trade(s):

• On Monday, April 14th, Raymond Dwek sold 3,000 shares of United Therapeutics stock. The shares were sold at an average price of $285.16, for a total value of $855,480.00.
• On Monday, April 7th, Raymond Dwek sold 4,000 shares of United Therapeutics stock. The stock was sold at an average price of $284.55, for a total value of $1,138,200.00.

United Therapeutics Stock Down 1.7 %

Shares of NASDAQ:UTHR traded down $5.04 during trading on Friday, hitting $291.38. 311,498 shares of the company traded hands, compared to its average volume of 447,735. The business's fifty day moving average is $308.67 and its 200-day moving average is $346.55. The stock has a market capitalization of $13.09 billion, a price-to-earnings ratio of 12.80, a PEG ratio of 0.97 and a beta of 0.63. United Therapeutics Co. has a one year low of $233.31 and a one year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, topping the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period last year, the company earned $4.36 earnings per share. On average, analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. MML Investors Services LLC acquired a new stake in United Therapeutics in the third quarter worth approximately $245,000. World Investment Advisors LLC bought a new stake in United Therapeutics in the third quarter worth about $393,000. Tidal Investments LLC raised its position in United Therapeutics by 33.1% in the third quarter. Tidal Investments LLC now owns 11,272 shares of the biotechnology company's stock worth $4,039,000 after acquiring an additional 2,803 shares in the last quarter. Tri Ri Asset Management Corp acquired a new stake in United Therapeutics in the 3rd quarter valued at about $7,686,000. Finally, Franklin Resources Inc. grew its stake in shares of United Therapeutics by 97.7% in the 3rd quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company's stock worth $89,532,000 after purchasing an additional 123,929 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

Wall Street Analysts Forecast Growth

UTHR has been the subject of several analyst reports. Bank of America upgraded shares of United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 target price for the company in a research note on Monday, April 21st. JPMorgan Chase & Co. dropped their target price on United Therapeutics from $357.00 to $355.00 and set an "overweight" rating on the stock in a research report on Monday, April 21st. HC Wainwright reissued a "buy" rating and issued a $425.00 price target on shares of United Therapeutics in a report on Thursday, February 27th. Wells Fargo & Company reaffirmed an "equal weight" rating and issued a $314.00 target price (down from $395.00) on shares of United Therapeutics in a research report on Friday. Finally, StockNews.com raised shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Thursday, April 17th. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $390.17.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.